Light source is critical to induce glioblastoma cell death by photodynamic therapy using chloro-aluminiumphtalocyanine albumin-based nanoparticles

Author(s)

Davanzo, Nathalia Nossi ^[1] ; Pellosi, Diogo Silva ^[1] ; Franchi, Leonardo Pereira ^[1] ; Tedesco, Antonio Claudio ^[1]

Affiliation

^[1] Univ Sao Paulo, Ctr Nanotechnol & Tissue Engn, Fac Philosophy Sci & Letters Ribeirao Preto, Photobiol & Photomed Res Grp, Dept Chem, Av Bandeirantes 3900, 14040-901 Vila Monte Alegre, Sao Paulo - Brazil

• Document type: Journal article
• Source: Photodiagnosis and Photodynamic Therapy; v. 19, p. 181-183, SEP 2017.
• Web of Science Citations: 7

Abstract

Selection of an efficient light source is fundamental in the development of photodynamic therapy (PDT) protocols. However, few studies provide a comparison of different light sources with regard to phototoxic effects. Here, we compared the cell death induced by photoactivation of chloro-aluminiumphtalocyanine (AlClPc)-loaded human serum albumin nanoparticles under irradiation with different light sources: continuous laser (CL), pulsed laser (PL), and light -emitting diode (LED). Cells were exposed to three different AIC1Pc concentrations (1, 3, and 5 mu M) and three different light doses (200, 500, and 700 mJ/cm(2)) for each light source. Cell death and differentiation of apoptosis and necrosis pathway were measured by flow cytometry. CL was the best light source for improving the photodynamic action of AlClPc-loaded albumin nanoparticles in glioblastoma cells and avoiding undesirable side effects, especially at low photosensitizer doses (200 mJ/cm(2)). In addition, apoptosis was the main cell death pathway in all evaluated cases (70% for CL, and greater than 50% for PL and LED). In conclusion, the search for optimal light sources and light/photosensitizer doses is a crucial step in improving PDT outcomes and enhancing the clinical translation of PDT. (AU)

• FAPESP's process: 16/00389-3 - MULTIFUNCTIONAL NANOPARTICLES FOR SITE-ESPECIFIC DELIVERY OF TEMOZOLOMIDE® AND VERTEPORFIN® FOR COMBINATION THERAPY OF BRAIN TUMORS
• Grantee: Diogo Silva Pellosi
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 13/50181-1 - Use of drugs containing nanocarriers with photosensitizers and/or other active compounds applied to cell therapy and treatment of central nervous system disorders
• Grantee: Antonio Claudio Tedesco
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 14/11870-9 - Sensitizing cancer cell lines to photodynamic therapy through inhibition of protein APE1
• Grantee: Leonardo Pereira Franchi
• Support Opportunities: Scholarships in Brazil - Post-Doctoral